The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a lancet ...

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...

WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ -- Even with the advancement of Automated Insulin ...

Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system. The approval builds ...

The world’s most connected continuous glucose monitoring system,† Dexcom G6, is now the first and only CGM to connect with the Omnipod® 5 Automated Insulin Delivery (AID) System in the United Kingdom.

The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...

Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...